SCHEMBL7074975

SCHEMBL7074975

Clc1ccc(CC2CC3CCC(C2)N3Cc2nc3ccccc3[nH]2)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 2/20 0.56
GRIN2B Q13224 2/20 0.56
DRD4 P21917 4/20 0.50
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
POLB P06746 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
IDO1 P14902 2/20 0.44
HTT P42858 1/20 0.43
GRM2 Q14416 1/20 0.43
DRD2 P14416 2/20 0.43
CXCR6 O00574 1/20 0.42
KDM4E B2RXH2 1/20 0.42
DRD3 P35462 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7072578 0.91 GRIN2B (0.67) GRIN1GRIN2BDRD4RAB9ANPC1
SCHEMBL7075826 0.89 GRIN1 (0.56) GRIN1GRIN2BDRD4RAB9ANPC1
SCHEMBL7074921 0.89 GRIN2B (0.56) GRIN1GRIN2BDRD4RAB9ANPC1
SCHEMBL7072074 0.88 GRIN1 (0.53) GRIN1GRIN2BDRD4TDP1MEN1
SCHEMBL7079118 0.88 GRIN1 (0.50) GRIN1GRIN2BDRD4IDO1HTT
SCHEMBL7072398 0.86 GRIN1 (0.53) GRIN1GRIN2BDRD4RAB9ANPC1
SCHEMBL6943866 0.84 DRD4 (0.39) GRIN1GRIN2BDRD4IDO1DRD2
SCHEMBL7076802 0.82 GRIN2B (0.56) GRIN1GRIN2BDRD4NPC1MEN1
SCHEMBL7073348 0.82 GRIN1 (0.53) GRIN1GRIN2BDRD4SMN1; SMN2KMT2A
SCHEMBL7079310 0.81 GRIN2B (0.50) GRIN1GRIN2BDRD4RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1244450-A4 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2003-03-19 EP claimed
EP-1244450-A1 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2002-10-02 EP claimed
US-6432976-B1 ANALGESICS; SIDE EFFECT REDUCTION MERCK & CO., INC. 2002-08-13 US claimed
WO-2001032179-A1 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2001-05-10 WO claimed
EP-1244450-A4 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2003-03-19 EP disclosed
EP-1248617-A4 2-AZA-BICYCLO 2.2.2]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2003-03-05 EP disclosed
US-6489477-B1 NMDA NR2B ANTAGONISTS. ACCORDINGLY, ANOTHER ASPECT OF THE INVENTION IS THE TREATMENT OF PAIN, MIGRAINE, DEPRESSION, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, OR STROKE--MALADIES THAT ARE AMENABLE TO AMELIORATION THROUGH MERCK & CO., INC. 2002-12-03 US disclosed
EP-1248617-A1 2-AZA-BICYCLO 2.2.2]OCTANE NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2002-10-16 EP disclosed
EP-1244450-A1 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2002-10-02 EP disclosed
US-6432976-B1 ANALGESICS; SIDE EFFECT REDUCTION MERCK & CO., INC. 2002-08-13 US disclosed
WO-2001032177-A1 2-AZA-BICYCLO[2.2.2]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2001-05-10 WO disclosed
WO-2001032179-A1 8-AZA-BICYCLO[3.2.1]OCTANE NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2001-05-10 WO disclosed